Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
AssigneeIcahn School of Medicine at Mount Sinai
InventorSpiros P. Hiotis
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions comprising mature dendritic cells loaded with autologous tumor cell lysates for the treatment of liver cancers, such as hepatocellular carcinoma. Hepatocellular carcinoma (HCC) is the fifth leading cancer and third leading cause of cancer-related mortality worldwide. Surgical resection and liver transplantation remain the mainstay of effective therapy for patients with early disease. However, a prevalent problem with HCC is the high likelihood of initial diagnosis at an advanced stage.
Claims10
An immunogenic composition consisting of dendritic cells (DCs) (i) autologous to a subject with a liver tumor, (ii) matured in the presence of lipopolysaccharide as the only maturation agent, (iii) loaded with hepatocellular (HCC) tumor cell lysate prepared by performing repeated freeze-thaw cycles of liver tumor cells obtained from the subject, and (iv) a pharmaceutically acceptable carrier or excipient;
- and
- wherein the DCs selectively reduce T regulatory cells (Tregs) in the liver tumor when administered to the subject.
Dependencies are inferred from the claim text.